Clinical Trials Logo
  1. Home
  2. B-Cell Malignancies
  3. NCT03642496

Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies

B-Cell Malignancies Clinical Trial

Official title:
The Clinical Study of Structurally Optimized ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies

Clinical Trial Summary

This study is to determine the safety, including potential dose limiting toxicities, and efficiency of ET019002-T cells and the duration of in vivo survival of ET019002-T cells in patients with relapsed/refractory B-Cell Malignancies.

Clinical Trial Description

ET019002-T cell therapy is a novel chimeric T-cell therapy platform that in preclinical studies, functionally matches the efficacy of CAR-T cells, but dramatically reduces the release of cytokines upon killing of target-positive tumors.The arm of the study is experimental i.v. arm:ET019002-T cells administered by intravenous (IV) infusion.The intervention is ET019002-T cells(Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET019002)-expression construct). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03642496
Study type Interventional
Source First Affiliated Hospital Xi'an Jiaotong University
Contact He Peng cheng, Doctor
Phone 0086-18991232609
Email hepc@163.com
Status Not yet recruiting
Phase Early Phase 1
Start date August 19, 2018
Completion date September 20, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT02343120 - Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies Phase 1/Phase 2
Completed NCT02018861 - A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) Phase 1/Phase 2
Terminated NCT03701438 - Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
Completed NCT02327078 - A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Phase 1/Phase 2
Completed NCT04551963 - Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies Phase 1
Recruiting NCT05683717 - A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies Phase 1
Completed NCT01775631 - Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma Phase 1
Active, not recruiting NCT01905813 - Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies Phase 1
Recruiting NCT05275504 - Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies Phase 1
Active, not recruiting NCT02457598 - Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies Phase 1
Recruiting NCT03050190 - A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies Phase 1/Phase 2
Recruiting NCT03125577 - Combination CAR-T Cell Therapy Targeting Hematological Malignancies Phase 1/Phase 2
Enrolling by invitation NCT04170283 - Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies Phase 3
Recruiting NCT04509700 - Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Phase 2
Completed NCT00983619 - A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies Phase 1/Phase 2